胃癌分子靶向治疗的研究进展

doi:10.11904/j.issn.1002-3070.2025.06.012

Abstract

Abstract: Gastric cancer is a malignant tumor with high incidence and poor prognosis worldwide,ranking fifth and fourth,among all malignancies interms of incidence and mortality.In China,the proportion of patients with advanced gastric cancer diagnosed for the first time is 64.37%.In recent years,with the in-depth research of molecular targets,targeted therapy for gastric cancer has made significant progress,and related target drugs such as HER2 and tight junction protein 18.2 subtypes(Claudin18.2,CLDN18.2)have shown clear clinical efficacy.From the first anti-HER2 monoclonal antibody trastuzumab approved for the treatment of gastric cancer,to the recently launched CLDN18.2 monoclonal antibody zolbetuximab,as well as many new targeted drugs in clinical research,it provides more treatment options for gastric cancer patients with different molecular subtypes.This article comprehensively reviews the research progress on targeted therapy and drug resistance mechanisms of gastric cancer,aiming to provide reference for clinical treatment decision-making and related basic research of gastric cancer.

Key words: gastric cancer, targeted therapy, molecular targets, human epidermal growth factor receptor 2, claudin18.2

CLC Number:

CAI Yiqing, DAI Enyong. Recent progress on molecular targeted therapy for gastric cancer[J]. Journal of Practical Oncology, 2025, 39(6): 542-550.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2025.06.012

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2025/V39/I6/542

References

1 Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
2 郑荣寿,陈茹,韩冰峰,等.2022年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2024,46(3):221-231.
3 Chen Y,Jia K,Xie Y,et al.The current landscape of gastric cancer and gastroesophageal junction cancer diagnosis and treatment in China:a comprehensive nationwide cohort analysis[J].J Hematol Oncol,2025,18(1):42.
4 赵雅茹.胃癌常见生物标记物及相应靶向治疗的研究进展[J].实用肿瘤学杂志,2022,36(5):483-488.
5 Yarden Y,Sliwkowski MX.Untangling the ErbB signalling network[J].Nat Rev Mol Cell Biol,2001,2(2):127-137.
6 Abrahao-Machado LF,Scapulatempo-Neto C.HER2 testing in gastric cancer:An update[J].World J Gastroenterolo,2016,22(19):4619.
7 Bang YJ,Van Cutsem E,Feyereislova A,et al.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer(ToGA):a phase 3,open-label,randomised controlled trial[J].Lancet,2010,376(9742):687-697.
8 Hofheinz RD,Hegewisch-Becker S,Kunzmann V,et al.Trastuzumab in combination with 5-fluorouracil,leucovorin,oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2-positive locally advanced esophagogastric adenocarcinoma:a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie Gastric Cancer Study Group[J].Int J Cancer,2021,149(6):1322-1331.
9 Rivera F,Izquierdo-Manuel M,García-Alfonso P,et al.Perioperative trastuzumab,capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma:NEOHX phase II trial[J].Eur J Cancer,2021,145:158-167.
10 Rivera F,Romero C,Jimenez-Fonseca P,et al.Phase II study to evaluate the efficacy of trastuzumab in combination with capecitabine and oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer:HERXO trial[J].Cancer Chemother Pharmacolo,2019,83(6):1175-1181.
11 Yuki S,Shinozaki K,Kashiwada T,et al.Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer:KSCC/HGCSG/CCOG/PerSeUS 1501B[J].Cancer Chemother Pharmacol,2020,85(1):217-223.
12 Makiyama A,Sukawa Y,Kashiwada T,et al.Randomized,phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer:WJOG7112G(T-ACT Study)[J].J Clin Oncol,2020,38(17):1919-1927.
13 Nordstrom JL,Gorlatov S,Zhang W,et al.Anti-tumor activity and toxicokinetics analysis of MGAH22,an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties[J].Breast Cancer Res,2011,13(6):R123.
14 Bang YJ,Giaccone G,Im SA,et al.First-in-human phase 1 study of margetuximab(MGAH22),an Fc-modified chimeric monoclonal antibody,in patients with HER2-positive advanced solid tumors[J].Ann Oncol,2017,28(4):855-861.
15 Catenacci DVT,Kang YK,Park H,et al.Margetuximab plus pembrolizumab in patients with previously treated,HER2-positive gastro-oesophageal adenocarcinoma(CP-MGAH22-05):A single-arm,phase 1b-2 trial[J].Lancet Oncol,2020,21(8):1066-1076.
16 Catenacci DVT,Kang YK,Yoon HH,et al.Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma:MAHOGANY cohort A[J].Esmo Open,2022,7(5):100563.
17 Moehler MH,Shitara K,Garrido M,et al.First-line(1L)nivolumab(NIVO)plus chemotherapy(chemo)versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma(GC/GEJC/EAC):Expanded efficacy and safety data from CheckMate 649[J].J Clin Oncol,2021,39(15_suppl):4002.
18 Ku G,Elimova E,Denlinger CS,et al.1380P Phase(Ph)II study of zanidatamab+ chemotherapy(chemo)in first-line(1L)HER2 expressing gastroesophageal adenocarcinoma(GEA)[J].ANN Oncol,2021,32:S1044-S1045.
19 Criscitiello C,Morganti S,Curigliano G.Antibody-drug conjugates in solid tumors:a look into novel targets[J].J Hematol Oncol,2021,14(1):20.
20 Ogitani Y,Hagihara K,Oitate M,et al.Bystander killing effect of DS-8201a,a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate,in tumors with human epidermal growth factor receptor 2 heterogeneity[J].Cancer Sci,2016,107(7):1039-1046.
21 Shitara K,Bang YJ,Iwasa S,et al.Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer[J].N Engl J Med,2020,382(25):2419-2430.
22 Yamaguchi K,Bang YJ,Iwasa S,et al.Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma:exploratory cohort results in a phase II trial[J].J Clin Oncol,2023,41(4):816-825.
23 Shitara K,Van Cutsem E,Gümüş M,et al.Trastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer[J].N Engl J Med,2025,393(4):336-348.
24 Dai L,Jin X,Wang L,et al.Efficacy of disitamab vedotin in treating HER2 2+/FISH-gastric cancer[J].Onco Targets Ther,2022,15:267-275.
25 Xu Y,Wang Y,Gong J,et al.Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors[J].Gastric Cancer,2021,24(4):913-925.
26 Peng Z,Liu T,Wei J,et al.Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing,locally advanced or metastatic gastric or gastroesophageal junction cancer:a single-arm phase II study[J].Cancer Commun(Lond),2021,41(11):1173-1182.
27 Shen L,et al.Disitamab vedotin(DV)plus toripalimab(Tor)and chemotherapy(C)/trastuzumab(Tra)as first-line(1L)treatment of patients(pts)with HER2-expressing locally advanced or metastatic(la/m)gastric cancer[J].J Clin Oncol,2025,43(17_suppl):LBA4012.
28 Hu X,Zhang Q,Wang L,et al.ACE-Breast-02:a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer[J].Signal Transduct Target Ther,2025,10(1):56.
29 Zhang Y,Qiu MZ,Wang JF,et al.Phase 1 multicenter,dose-expansion study of ARX788 as monotherapy in HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma[J].Cell reports Medicine,2022,3(11):100814.
30 Haffner I,Schierle K,Raimundez E,et al.HER2 expression,test deviations,and their impact on survival in metastatic gastric cancer:results from the prospective multicenter VARIANZ study[J].J Clin Oncol,2021,39(13):1468-1478.
31 Seo S,Ryu MH,Park YS,et al.Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients:results of the GASTric cancer HER2 reassessment study 3(GASTHER3)[J].Gastric Cancer,2019,22(3):527-535.
32 Janjigian YY,Sanchez-Vega F,Jonsson P,et al.Genetic predictors of response to systemic therapy in esophagogastric cancer[J].Cancer Discov,2018,8(1):49-58.
33 Sampera A,Sánchez-Martín FJ,Arpí O,et al.HER-family ligands promote acquired resistance to trastuzumab in gastric cancer[J].Mol Cancer Ther,2019,18(11):2135-2145.
34 Sahin U,K oslowski M,Dhaene K,et al.Claudin 18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development[J].Clin Cancer Res,2008,14(23):7624-7634.
35 Rohde C,Yamaguchi R,Mukhina S,et al.Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma[J].Jpn J Clin Oncol,2019,49(9):870-876.
36 Hong JY,An JY,Lee J,et al.Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer[J].Transl Cancer Res,2020,9(5):3367-3374.
37 Pellino A,Brignola S,Riello E,et al.Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas[J].J Pers Med,2021,11(11):1095.
38 Singh P,Toom S,Huang Y.Anti-claudin 18.2 antibody as new targeted therapy for advanced gastric cancer[J].J Hematol Oncol,2017,10(1):105.
39 Türeci O,Sahin U,Schulze-Bergkamen H,et al.A multicentre,phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus:the MONO study[J].Ann Oncol,2019,30(9):1487-1495.
40 Sahin U,Türeci Ö,Manikhas G,et al.FAST:a randomised phase II study of zolbetuximab(IMAB362)plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma[J].Ann Oncol,2021,32(5):609-619.
41 Shitara K,Lordick F,Bang YJ,et al.Zolbetuximab+ mFOLFOX6 as first-line(1L)treatment for patients(pts)withclaudin-18.2+(CLDN18.2+)/HER2-locally advanced(LA)unresectable or metastatic gastric or gastroesophageal junction(mG/GEJ)adenocarcinoma:primary results from phase 3 SPOTLIGHT study[J].Lancet,2023,401(10383):1655-1668.
42 Xu R,Shitara K,Ajani J A,et al.Zolbetuximab+ CAPOX in 1L claudin-18.2+(CLDN18.2+)/HER2-locally advanced(LA)or metastatic gastric or gastroesophageal junction(mG/GEJ)adenocarcinoma:Primary phase 3 results from GLOW[J].Net Med,2023,29(8):2133-2141.
43 Xu G,Liu W,Wang Y,et al.CMG901,a Claudin18.2-specific antibody-drug conjugate,for the treatment of solid tumors[J].Cell Rept Med,2024,5(9):101710.
44 Ruan DY,Liu FR,Wei XL,et al.Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer(KYM901):a multicentre,open-label,single-arm,phase 1 trial[J].Lancet Oncol,2025,26(2):227-238.
45 Liu J,Yang J,Sun Y,et al.CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma:a phase 1 trial[J].Nat Med,2025,31:3028-3036.
46 Huang W,Li Y,Liu Z,et al.Preclinical activity for TPX-4589(LM-302),an antibody-drug conjugate targeting tight junction protein CLDN18.2 in solid tumors[J].Eur J Cancer,2022,174:S41-S42.
47 Bai C,Xue J,Zheng Y,et al.A phase 1/2 study of LM-302,an anti-claudin 18.2(CLDN18.2)antibody-drug conjugate in patients with advanced gastric/gastroesophageal junction cancer[J].J Clin Oncol,2024,42(16):3028.
48 Jiang HP,et al.Efficacy and safety of LM-302(anti-claudin 18.2 ADC)in combination with anti-PD-1 therapy for advanced gastric,gastroesophageal junction cancer and esophageal adenocarcinoma:Early-phase study results[J].J Clin Oncol,2025,43:4039.
49 Jiang H,Shi Z,Wang P,et al.Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer[J].J Nat Cancer Inst,2019,111(4):409-418.
50 Qi C,Gong J,Li J,et al.Claudin18.2-specific CAR T cells in gastrointestinal cancers:phase 1 trial interim results[J].Nat Med,2022,28(6):1189-1198.
51 Dantzig AH,Hoskins JA,Tabas LB,et al.Association of intestinal peptide transport with a protein related to the cadherin superfamily[J].Science,1994,264(5157):430-433.
52 Altree-Tacha D,Tyrrell J,Haas T.CDH17 is a more sensitive marker for gastric adenocarcinoma than CK20 and CDX2[J].Arch Pathol Lab Med,2017,141(1):144-150.
53 Wang R,Fang P,Chen X,et al.Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor[J].Cell Rep Med,2025,6(7):102213.
54 Yu J,Chen M,Sang Q,et al.Super-enhancer activates master transcription factor NR3C1 expression and promotes 5-FU resistance in gastric cancer[J].Adv Sci(Weinh),2025,12(7):e2409050.
55 蒋小华,魏淑红.Trop2靶向药物在肿瘤治疗中的前景[J].中国细胞生物学学报,2020,42(7):1239-1246.
56 Bardia A,Mayer IA,Vahdat LT,et al.Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J].N Engl J Med,2019,380(8):741-751.
57 Cardillo TM,Govindan SV,Sharkey RM,et al.Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers:preclinical studies in human cancer xenograft models and monkeys[J].Clin Cancer Res,2011,17(10):3157-3169.
58 Okajima D,Yasuda S,Maejima T,et al.Datopotamab deruxtecan,a novel TROP2-directed antibody-drug conjugate,demonstrates potent antitumor activity by efficient drug delivery to tumor cells[J].Mol Cancer Ther,2021,20(12):2329-2340.

[1]	ZHAO Jian, LIU Changqing, GAI Yi, REN Jing, WANG Yusheng, WANG Guangyu. Evaluation of the efficacy and safety of ramucirumab in patients with advanced gastric cancer or gastroesophageal junction cancer:A retrospective observational study [J]. Journal of Practical Oncology, 2025, 39(6): 527-534.
[2]	ZHAO Zhilong, HOU Junming. Research progress on the mechanism and therapeutic targets of extracellular matrix in pancreatic cancer [J]. Journal of Practical Oncology, 2025, 39(6): 535-541.
[3]	LI Yun, SHI Pinghui. Analysis of gastroscopic screening and follow-up results among high-risk populations for gastric cancer in Gejiu City,Yunnan Province [J]. Journal of Practical Oncology, 2025, 39(5): 405-411.
[4]	DAI Fengxue, WANG Zhenfei. Research progress on the potential role and mechanism of hydrogen sulfide in the treatment of gastric cancer [J]. Journal of Practical Oncology, 2025, 39(4): 330-337.
[5]	CHEN Lijuan, MA Xinxin, GAO Guangqiang, TIAN Hong, LIU Jiaren. Research on the mechanism of dihydroactiniolide in inhibiting the proliferation of gastric cancer cells [J]. Journal of Practical Oncology, 2025, 39(2): 91-98.
[6]	MA Ming, WANG Wanying, RUAN Yuli, LIU Chao, ZHANG Yanqiao, MA Zhigang. The values of systemic inflammatory immune nutritional score in predicting the prognosis of immunotherapy for advanced gastric cancer [J]. Journal of Practical Oncology, 2025, 39(1): 39-48.
[7]	KONG Hongqian, DONG Juan, WEN Hongmei, SHAO Ying, CHENG Huirong, YU Qiuli. Analysis of gastric cancer incidence and mortality in cancer registration areas of Yunnan province in 2020 and the trends from 2012 to 2020 [J]. Journal of Practical Oncology, 2024, 38(6): 372-376.
[8]	SHAO Yuming, ZHU Kunbing, ZHANG Jie. Research progress of SP/NK-1R system in breast cancer [J]. Journal of Practical Oncology, 2024, 38(4): 268-272.
[9]	LIAO Jun, LI Chunfeng, XUE Yingwei, ZU Hongliang. Research progress of lactate dehydrogenase in the diagnosis and treatment of gastric cancer [J]. Journal of Practical Oncology, 2024, 38(3): 200-206.
[10]	Breast Oncology Group of Heilongjiang Medical Association. Expert consensus on clinicopathological diagnosis of breast cancer with low expression of HER2 in Heilongjiang province(2024 edition) [J]. Journal of Practical Oncology, 2024, 38(2): 71-78.
[11]	YANG Peng, LUO Jinmei, LUO Ping, XIE Xiaobo. An immune score model based on immune cell infiltration predicts the effects of immunotherapy and prognosis of early gastric cancer [J]. Journal of Practical Oncology, 2024, 38(2): 121-130.
[12]	GAO Chaofeng, ZHAO Zekun, WEI Fengxian, SUN Yuan, ZHOU Zhiming, XU Xiaodong. Research progress on perioperative nutritional management for gastric cancer [J]. Journal of Practical Oncology, 2023, 37(6): 519-523.
[13]	FAN Tingting, DING Danni, ZHAO Zixue, YU Yang, HAN Fengjuan. Fatty acid metabolism and ovarian cancer [J]. Journal of Practical Oncology, 2023, 37(5): 429-433.
[14]	FU Xinya, HU Lingdan, ZHANG Zhijian, MA Xiumei. HPA promotes the invasion and metastasis of human gastric cancer cells by up-regulating MCP1/CCR2 [J]. Journal of Practical Oncology, 2023, 37(4): 329-336.
[15]	LI Juan, LIU Jiaren. The current research status and progress of immunotherapy for gastric cancer [J]. Journal of Practical Oncology, 2023, 37(4): 372-376.

Recent progress on molecular targeted therapy for gastric cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments